

PRODUCT INFORMATION



NO-1886

Item No. 17425

CAS Registry No.: 133208-93-2

Formal Name: [[4-[[[(4-bromo-2-cyanophenyl)amino]carbonyl]phenyl]methyl]-phosphonic acid diethyl ester

Synonyms: Ibrolipim, Lipoprotein Lipase Activator, LPL Activator, OPF 009

MF: C₁₉H₂₀BrN₂O₄P

FW: 451.3


Purity: ≥98%

UV/Vis.: λ_{max}: 260 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

NO-1886 is supplied as a crystalline solid. A stock solution may be made by dissolving the NO-1886 in the solvent of choice, which should be purged with an inert gas. NO-1886 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of NO-1886 in ethanol is approximately 2 mg/ml and approximately 25 mg/ml in DMSO and DMF.

NO-1886 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, NO-1886 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. NO-1886 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Lipoprotein lipase (LPL) mediates the hydrolysis of triglycerides in circulating very low density lipoproteins and chylomicrons.^{1,2} NO-1886 is an LPL activator that increases LPL mRNA and LPL activity in adipose tissue, myocardium, and skeletal muscle.³ This coincides with an elevation in post-heparin plasma LPL activity and LPL mass in rats.^{3,4} NO-1886 decreases plasma triglyceride concentration and increases plasma high-density lipoprotein cholesterol, resulting in inhibited development of atherosclerotic lesions in coronary arteries and aortas of rats and rabbits.^{3,4}

References

1. Kim, M.S., Wang, Y., and Rodrigues, B. Lipoprotein lipase mediated fatty acid delivery and its impact in diabetic cardiomyopathy. *Biochim. Biophys. Acta* **1821(5)**, 800-808 (2011).
2. Olivecrona, G. and Olivecrona, T. Triglyceride lipases and atherosclerosis. *Curr. Opin. Lipidol.* **21**, 409-415 (2010).
3. Yin, W. and Tsutsumi, K. Lipoprotein lipase activator NO-1886. *Cardiovasc. Drug Rev.* **21(2)**, 133-142 (2003).
4. Tsutsumi, K., Inoue, Y., Shima, A., *et al.* The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. *J. Clin. Invest.* **92(1)**, 411-417 (1993).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/10/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM